Mutational and Immunohistochemical Study of the PI3K/Akt Pathway in Papillary Thyroid Carcinoma in Greece

被引:15
作者
Sozopoulos, Elias [1 ]
Litsiou, Helen [1 ]
Voutsinas, Gerassimos [2 ]
Mitsiades, Nikolaos [3 ]
Anagnostakis, Nikolaos [1 ]
Tseva, Thomais [1 ]
Patsouris, Efstratios [1 ]
Tseleni-Balafouta, Sofia [1 ]
机构
[1] Univ Athens, Sch Med, Dept Pathol 1, GR-11527 Athens, Greece
[2] Natl Ctr Sci Res Demokritos, Lab Environm Mutagenesis & Carcinogenesis, Inst Biol, Athens, Greece
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
PI3K/Akt pathway; Thyroid cancer; Papillary carcinoma; Mutational analysis; GROWTH-FACTOR-I; HORMONE-INDEPENDENT PROLIFERATION; EPITHELIAL-CELLS; IGF-I; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; ENDOMETRIAL CARCINOMAS; RET/PTC REARRANGEMENTS; PHOSPHATASE-ACTIVITY; GENETIC ALTERATIONS; GERMLINE MUTATIONS;
D O I
10.1007/s12022-010-9112-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PI3K/Akt signaling pathway plays critical role in many cell processes. There is indication that enhanced activation of PI3K/Akt cascade is implicated in thyroid tumors. Aim of this study was to evaluate the mutational status and expression of PI3K/Akt pathway mediators in papillary thyroid carcinoma in Greece. We evaluated the presence of mutations in PIK3CA (exons 9 and 20), AKT1 (exons 6-11), AKT2 (exons 6-11), AKT3 (exons 5-10), PTEN (exons 3-8), and PDPK1 (exons 4-10) genes in 83 papillary thyroid carcinomas by DNA sequencing. The expression levels of phospho-Akt and insulin-like growth factor I receptor (IGF-IR) were evaluated by immunohistochemistry. PIK3CA mutations were found in three samples. The analysis of AKT1 revealed one silent mutation in exon 9 (G726A) in 16 samples. One specimen carried an AKT3 mutation. One missense mutation was found in one sample in PTEN. No mutations were found in AKT2 and PDPK1. Increased levels of phosphorylated total Akt and IGF-IR were identified in some papillary cancers. Our findings indicate that PI3K/Akt signaling pathway is activated in some papillary tumors. However, mutations in genes coding most mediators of the pathway have not been proven to be the major modus of enhanced activation. These data suggest a potential role for PI3K/Akt-mediated signaling in papillary thyroid tumors.
引用
收藏
页码:90 / 100
页数:11
相关论文
共 68 条
[1]   Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity [J].
Ali, IU ;
Schriml, LM ;
Dean, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (22) :1922-1932
[2]   The IGF-I receptor and cancer [J].
Baserga, R ;
Resnicoff, M ;
Dews, M .
ENDOCRINE, 1997, 7 (01) :99-102
[3]   The igf-1 receptor in cancer biology [J].
Baserga, R ;
Peruzzi, F ;
Reiss, K .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) :873-877
[4]  
BERGMANN U, 1995, CANCER RES, V55, P2007
[5]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[6]   Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation [J].
Cass, LA ;
Meinkoth, JL .
ONCOGENE, 2000, 19 (07) :924-932
[7]   Phosphorylated Insulin Like Growth Factor-I Receptor Expression and Its Clinico-Pathological Significance in Histologic Subtypes of Human Thyroid Cancer [J].
Chakravarty, Geetika ;
Santillan, Alfredo A. ;
Galer, Chad ;
Adams, Henry P. ;
El-Naggar, Abdal K. ;
Jasser, Samar A. ;
Mohsin, Sayed ;
Mondal, Debasis ;
Clayman, Gary L. ;
Myers, Jeffrey N. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 234 (04) :372-386
[8]  
Dahia PLM, 1997, CANCER RES, V57, P4710
[9]  
De Vita G, 2000, CANCER RES, V60, P3916
[10]  
De Vita G, 2000, CANCER RES, V60, P3727